Visual Abstract: Safety, Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease - For The Media

JAMA Neurology

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, JUNE 13, 2022

Media advisory: The full study is linked to this news release. A visual abstract is below.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2022.1375?guestAccessKey=4a71cc83-4774-4e0f-96c7-7d55962a81f5&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061322

Visual Abstract

Authors: Edmond Teng, M.D., Ph.D., of Genentech Inc., in South San Francisco, California, is the corresponding author.

(doi:10.1001/jamaneurol.2022.1375)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.